Please Wait.....
Report
Global Cell Based Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-04-28 I 110 Pages I Mordor Intelligence
The Global Cell Based Immunotherapy Market size is estimated at USD 5.24 billion in 2025, and is expected to reach USD 10.54 billion by 2030, at a CAGR of 14.98% during the forecast period (2025-2030).
COVID-19 had a significant impact on the cell-based immunotherapy market during the initial phases owing to the factors such as delayed elective surgeries, follow-up appointments, and some types of cancer treatments being canceled or postponed as hospitals prioritized beds and care for those patients who were seriously ill with COVID-19. For instance, as per an article published in March 2022 in PubMed, affected by the epidemic, many patients who were receiving subcutaneous immunotherapy (SCIT) were compelled to discontinue or postpone it.
Interestingly, cell-based immunotherapies were used for COVID-19 treatments during the pandemic. For instance, as per an article published in June 2022 in PubMed, innovative adaptive immune cell treatment gave patients with moderate-to-severe COVID-19 a viable preventative or therapeutic option. This strategy aimed to increase security, provide safe and efficient therapy, and supplement routine therapy for all COVID-19-infected patients. Post-pandemic, the market is anticipated to witness growth due to the rising prevalence of cancer, technological advancement in developing target-based anticancer therapy, and launches and approval of different cell-based immunotherapy.
For instance, as per an American Cancer Society 2022 update, the estimated number of new cancer cases was 1.9 million in 2022 in the United States. Additionally, the advancements in products, increasing approvals, clinical trials along with partnerships and collaborations by key players are helping the market growth. In June 2022 Immuneel Therapeutics, a biotech start-up commenced patient dosing in a CAR-T trial named IMAGINE. This phase II trial, which is currently actively enlisting patients in Bengaluru for clinical trial development, is one of the first industry-sponsored CAR-T trials in India. Such clinical trial developments are expected to augment the demand for cell-based immunotherapy. Furthermore, a rise in research and development in cell-based cancer therapy is likely to drive market growth over the forecast period. For instance, as per an article published in June 2022 in Frontiers, the majority of the current evaluation-stage strategies take advantage of the safety of T-cell activation and incorporate tumor-targeting mechanisms, such as chimeric antigen receptors (CARs) or bispecific T cell engagers (bsTCEs), which is likely to be essential to achieving more robust and reliable clinical responses.
Therefore, due to several factors, the cell-based immunotherapy market is anticipated to witness growth over the analysis period. However, the high cost of technology and lack of awareness in developing markets is likely to impede the market growth.
Cell-Based Immunotherapy Market Trends
Chimeric Antigen Receptor (CAR) T-Cell Therapy Is Expected To Witness Significant Growth Over The Forecast Period
Chimeric antigen receptor (CAR) T-cell therapy is a significant advancement in cancer treatment. In this therapy, the patient's T cells are genetically engineered to express an artificial receptor that binds to a tumor antigen. CAR-T cell therapy acts against CD19-coded cancer antigens to treat B-cell cancers. The rising prevalence of cancer, technological advancement in developing target-based anti-cancer therapies, and the increased adoption of cell-based therapy for therapeutic purposes are the key driving factors in the chimeric antigen receptor (CAR) T-cell therapy segment.
For instance, as per an American Cancer Society 2022 update, an estimated 10,470 children (ages 0 to 14 years) and 5,480 adolescents (ages 15-19 years) were likely to be diagnosed with cancer in the United States in 2022.
The advancements in therapy, approvals, launches, partnerships, and acquisitions by the key market players are also likely to boost segment growth. For instance, in May 2022, The European Commission (EC) approved Janssen's CAR-T therapy, Carvykti, for adults with heavily pre-treated, relapsed, and refractory multiple myeloma, marking the treatment's first approval outside of the US. Also, in March 2021 the FDA approved Abecma (idecabtagene vicleucel), the first cell-based gene therapy to treat adult multiple myeloma patients who have not responded to at least four prior rounds of therapy. It is a genetically engineered chimeric antigen receptor (CAR) T-cell therapy directed by the B-cell maturation antigen (BCMA).
North America is Expected to Witness a Growth in the Cell Based Immunotherapy Market Over The Forecast Period
North America is expected to hold a significant market share in the global cell-based immunotherapy market due to the rising prevalence of cancer, the growing awareness of cell-based therapies, the strong presence of industry players, and better healthcare infrastructure in this region. For instance, according to an American Cancer Society 2022 update, in the United States, 290,560 new cases of breast cancer, 89,010 cases of lymphoma, 62,210 cases of pancreatic cancer, 106,180 cases of colon cancer, and 44,850 cases of rectum cancer were anticipated to be diagnosed in 2022.
Furthermore, ongoing research in cancer treatment, technological advancements, product approvals, launches, partnerships, and acquisitions by the key market players also fuels the growth of the overall regional market to a large extent. For instance, in May 2022, the U.S. Food and Drug Administration (FDA) expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The accelerated approval was granted to Novartis for the chimeric antigen receptor (CAR) T-cell therapy Kymriah (tisagenlecleucel), making it the third indication for personalized cellular therapy for cancer. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.
Cell-Based Immunotherapy Industry Overview
The cell-based immunotherapy market is consolidated, moderately competitive, and has a few major players. The companies currently dominating the market are Novartis AG, Gilead Sciences, Inc (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co., Ltd, and GC Biopharma Corporation.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer
4.2.2 Technological Advancement in Developing Target Based Anti-Cancer Therapies
4.2.3 Launches and Approval of Different Cell-based Immunotherapy Drugs
4.3 Market Restraints
4.3.1 High Cost of Technology
4.3.2 Lack of Awareness in the Developing Markets
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapy
5.1.1 Autologous Cellular Immunotherapy
5.1.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy
5.1.3 Dendritic Cell-based Vaccine Therapy
5.2 By Primary Indication
5.2.1 B-cell Malignancies
5.2.2 Prostate Cancer
5.2.3 Renal Cell Carcinoma
5.2.4 Liver Cancer
5.2.5 Other Primary Indications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Gilead Sciences, Inc (Kite Pharma)
6.1.3 GC Biopharma Corporation
6.1.4 Dendreon Pharmaceuticals LLC
6.1.5 JW CreaGene Co., Ltd
6.1.6 GC Biopharma Corporation
6.1.7 Johnson and Johnson (Janssen Global Services, LLC)
6.1.8 Pfizer Inc.
6.1.9 F. Hoffmann-La Roche Ltd
6.1.10 GlaxoSmithKline plc
6.1.11 Celyad
6.1.12 Bristol-Myers Squibb Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security